Predicta Biosciences, a company focused on precision oncology, has secured an oversubscribed seed round of $5.2 million. The round was led by The Engine Ventures, with Illumina Ventures, Time Boost Capital, American Cancer Society Bright Edge, and the Oetgen family as participating investors.
Founded by leading cancer genomics researchers and clinicians, Predicta is developing a novel, non-invasive diagnostic for multiple myeloma. This diagnostic aims to provide more comprehensive information on patients’ disease status, including their immune system cells. This information can aid physicians in determining patients’ likelihood of responding to immunotherapies, such as CAR T-cell therapy and bispecific antibodies.
The company’s diagnostic platform leverages sophisticated algorithmic analysis for risk stratification and treatment optimization. It is designed to replace painful bone marrow biopsies with simple blood draws, offering a less invasive and more convenient approach to diagnosis and monitoring.
Predicta’s first product, GenoPredicta, is currently being used in research at Dana Farber Cancer Institute. The company plans to launch the diagnostic product commercially in the future. Predicta aims to improve patient outcomes and advance precision medicine in cancer treatment by addressing the unmet need for non-invasive diagnostics in multiple myeloma.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
